Background: 5-HT 3 antagonists are effective in reducing the acute nausea and vomiting caused by cancer chemotherapy. However, it is not clear whether continuing these agents beyond twenty four hours is useful in controlling emesis on days two to seven after chemotherapy.
Introduction

5-HT
antagonists have become established as effective agents in the management of nausea and vomiting induced by cancer chemotherapy [1] . Despite numerous studies, however, questions remain about the optimal use of these drugs [2] . One area of controversy is whether there is benefit in continuing their administration after 24 hours in order to prevent the development or reduce the frequency of nausea and vomiting in this 'delayed' phase. There are only limited data from randomized trials in which the only variable was the addition of a 5-HT 3 antagonist during the delayed phase. In a study carried out by our group, continuation of granisetron did not add to the efficacy of dexamethasone after high dose cisplatin chemotherapy [3] . Another randomized trial did, however, find a non-significant difference in favor of continued ondansetron therapy [4] in this context and a recent study demonstrated a statistically significant advantage over placebo [5] . In patients receiving moderately emetogenic chemotherapy (see Table 2 for definition) two randomized trials addressing the role of adding 5-HT 3 antagonists in the delayed phase have been conducted. Both showed a statistically significant advantage to administering ondansetron as opposed to placebo on days two through five [6, 7] .
Although the issue of delayed emesis after high-dose cisplatin has received more attention, this problem is also important in patients receiving moderately emetogenic chemotherapy. For example, in the study just cited [6] , we found that of 68 patients who had no post-chemotherapy vomiting in the 24 hours after administration of ondansetron and dexamethasone prior to chemotherapy, 28 (41%) vomited in the next four days when no further anti-emetics were given. This frequency was reduced to 15/75 (20%) when ondansetron was continued.
All the studies cited above which showed a benefit to continuing a 5-HT 3 antagonist involved comparisons to no active therapy. Whether similar gains could be achieved by other drugs with anti-emetic activity is not known. Steroids and the combination of steroids and metoclopramide have been found to reduce delayed emesis in patients receiving high-dose cisplatin [8, 9] . In addition, one study has suggested that continuing steroids might be beneficial in patients receiving moderately emetogenic chemotherapy [10] . Thus we decided in design- ing the trial to be reported here to address the question of whether continuation of a 5-HT 3 antagonist added benefit to a potentially active and less expensive therapydexamethasone.
Patients and methods
This study of the role of 'maintenance' therapy was a component of a larger trial aimed at addressing several issues in the management of nausea and vomiting after moderately emetogenic chemotherapy [11] . The overall study design is described m Table 1 . Patients were enrolled on one of six treatment arms constructed so that two or more arms could be combined in factorial comparisons of ondansetron versus dolasetron and additional dexamethasone versus no additional dexamethasone in controlling acute and delayed nausea and vomiting. The addition of arms two and six to the study design allowed consideration of the question addressed here, i.e., does the addition of 5-HT 3 antagonists to steroids improve control of nausea and vomiting after day one (arms three, five vs. arms two, six) since this comparison could then be made in patients whose treatment differed only after 24 hours.
Inclusion criteria for the trial are listed in Table 2 . Of note is the fact that patients receiving multiple day chemotherapy were eligible for the trial provided that the emetogenic agents were given in the same dose each day. Such patients received intravenous anti-emetics days one to three and oral anti-emetics days four to seven. Because results in such patients might be confounded by the continuation of their day one treatments, analyses both including and excluding them were done. For the sake of brevity, separate results from these analyses are only presented in the one case where they differ.
Patients recorded their experiences after chemotherapy in self report diaries in which they listed all episodes of emesis and their times of onset as well as the severity of nausea experienced over specific time periods. Similar diaries have been successfully used in trials by our group [12] and others [13] and have been previously validated. For this study, patients were considered to have a 'complete response' with respect to emesis if: 1) no episodes of emesis were reported; 2) no 'rescue' medications was administered even if emesis had not occurred; and 3) no data were missing for the time period in question. Free of significant cardiac disease and without ECG evidence of conduction abnormality ECOG performance status < 2
Not pregnant, not taking anti-convulsants and free of major renal or hepatic dysfunction failed to complete all sections of the diary were considered not to have achieved the complete response criterion and were considered to have had an 'event' at the tune medications were taken or data were missing. The result for nausea was expressed as the mean of the 100 mm VAS nausea severity scales completed over the seven day time period. In this case, time periods with missing information were excluded from the calculation of the mean value unless they represented more than 50% of the study period in which case the patient was excluded. Quality-of-life was also assessed. The instrument used was the EORTC QLQ-C30 [14] . It was administered prior to chemotherapy (within 72 hours) and again either on day four or day eight after chemotherapy. The selection of day four or eight was randomized by center as part of another study designed to examine the effect of the timing of quality of life assessment. The timeframes of the questionnaires were also randomly varied to be either four or seven days. For the purposes of this report quality of life outcomes were analyzed as changes from baseline as measured either at day four or day eight.
Statistical analyses were conducted in SAS [15] . The analysis of the effect of treatment assignment on the outcome 'complete response for seven days' was assessed with the Mantel-Haenszel chi-square statistic adjusted for type of 5-HT3 antagonists as well as stratification variables (chemotherapy regimen and centre size). A multiple logistic regression was also carried out which controlled for stratification variables as well as baseline characteristics found significant on univariate analysis. Time to first episode of emesis was evaluated in a similar fashion using the Cox proportional hazards method. Comparison of mean nausea severity was conducted with an analysis of variance model adjusting for the same factors as the logistic regression. Quality-of-life was analyzed in a fashion similar to nausea severity. In this case results were adjusted for the day of post-chemotherapy assessment and the timeframe of the questionnaire. The sample size for the overall trial was set to meet the primary objectives of the study. For this portion of the trial, it provided a power of 80% to detect a difference in seven day complete control rates of 13% at an alpha of 0.05 (one-sided). In keeping with the design of the study />-values reported for the primary outcomes nausea and vomiting are one-sided. Two-sided values can be obtained by multiplying by two. Other f-values are two-sided.
The study was conducted as a joint venture of the Clinical Trials Group of the National Cancer Institute of Canada (NCIC CTG) and Hoechst Marion Roussel Canada Research Inc. (HMRCRT) Randomization lists were generated by NCIC CTG. All randomizations were obtained by phoning the NCIC CTG central office. Data were reported on case report forms reviewed in participating centres by clinical research associates employed by HMRCRI and then forwarded to NCIC (49) 29 (40) 28 (28) 16(22) 15 (21) 42 (58) 8 (11) 4(5) (50) 58 (46) 46 (37) 21(17) 41 (32) 57 (46) 13 (11) 13(10) (56) 32 (47) 19 (28) 17 25) 18(26) 38 (56) 6 (8) 17(10) ' #/% patients from centres enrolling less than 15 patients. CTG to be entered into its database. All case report forms were reviewed internally and separately by NCIC CTG and HMRCRI. Final disposition of 'problem' cases (i.e., questionable eligibility or evaluability) or adjudication of unclear outcomes (e.g., inconsistent diary reports) was accomplished in a blinded consensus review by representatives of the two Groups (JP, ED and BZ). Allocation codes were possessed only by NCIC CTG and the study was unblinded only after accrual was complete and all data were finalized. Thus, no interim analyses were conducted (or planned). The study was approved by the ethics boards of all participating institutions. All patients gave written informed consent.
Results
The trial opened in May 1993 and closed in January 1995 after enrolling 703 patients on all six arms. Four hundred seven patients were entered on the four arms relevant to the objective of the study addressed in this report. Of these, five were ineligible because they did not receive study medication even though they had consented to the trial and had received an allocation. Four hundred two patients are therefore included in this analysis. Their characteristics are listed in Table 3 . The distribution is well-balanced among the arms. The complete control rate over seven days for patients on the 5-HT 3 added arms was 47% and for those on the dexamethasone alone arms was 41%. These differences were not significant (P = 0.24, one-sided) in an analysis stratified for anti-emetic regimen, chemotherapy regimen and centre size nor in a logistic regression (P = 0.19, onesided) which included stratification variables and baseline characteristics significantly related to this outcome (performance status, age, and presence of metastatic disease).
Control of emesis in the two patient groups is portrayed graphically in Figure 1 which displays the proportion of patients remaining failure-free over the seven study days. (The 'drop-off on day seven is due to missing data). The difference between these two curves is not significant in an analysis adjusted for stratification variables nor in a Cox model adjusted for stratification variables and significant prognostic factors.
Patients receiving 5-HT 3 antagonists did, however, have a reduced mean nausea severity (6 mm) over seven days compared to those on dexamethasone (9 mm). This 3 mm difference was statistically significant on univariate and multivariate analyses (P = 0.015 and 0.01 one sided, respectively).
The EORTC QLQ-C30 contains five functional domains, nine symptom scales, and a two question assessment of overall quality-of-life. Of these, only two were significantly different between the two treatment groups. Social functioning deteriorated significantly (P = 0.03) more (-6.0 points on a 100 point scale) in patients on dexamethasone alone then in those receiving both drugs (-0.81 points). On the other hand patients taking 5-HT 3 antagonists reported a significantly (P = 0.001) greater increase in constipation (26 points on a 100 point scale) than did those on dexamethasone alone (13 points). Exclusion of multiple day patients resulted in there also being a significant differences in the extent of deterioration in global quality of life (P = 0.03) (-7.7 vs. -1.1 points on a 100 point scale) and in physical functioning (P = 0.05) (-11.7 vs. -1.1 points on a 100 point scale) in favour of the 5-HT 3 added arms.
Discussion
The results reported here suggest that continuing 5-HT 3 antagonists after day one has at best a modest impact on the experience of patients receiving moderately emetogenic chemotherapy who are taking dexamethasone during this period. It is possible that the statistically significant differences in nausea severity and in quality of life were chance observations, since several endpoints were considered. However, the trend of the emesis data was in the same direction, as were other quality of life para-meters. The results of previous trials [5, 6] in this setting further support the interpretation that these findings represent a real biologic effect of 5-HT 3 antagonists.
Assessing the clinical importance of these differences is more problematic. The difference in nausea severity found was less than that which triggered patient preference in a previous trial [10] , suggesting these statistically significant differences might not be clinically important. A body of work does exist addressing the question of what differences in quality of life outcomes are clinically significant [16] , but it does not deal with the EORTC QLQ-C30. Further, there is no method for weighting the sub-components of the QLQ-C30 with respect to their overall importance. Thus, it is difficult to balance symptomatic changes in one direction (i.e., constipation) against functional changes (i.e., social functioning) in another.
Another unavoidable consideration is the substantial cost of a strategy of routinely continuing 5-HT3 antagonists for seven days after chemotherapy. A shorter duration of therapy might have achieved the same results, but this study was not designed to assess such a strategy.
Thus, a larger trial specifically addressing issues of cost and clinical significance may be necessary to resolve this issue. Meanwhile, our results represent the only randomized data bearing on the question of whether adding 5-HT 3 antagonists to steroids is beneficial in patients receiving moderately emetogenic chemotherapy. Until other studies are done or reported we feel our findings should be taken into account in formulating approaches to patient management. Our view is that such consideration should lead to restraint in the routine use of 5-HT3 antagonists in these circumstances.
